Time from randomisation until discontinuation of ventilation (for those ventilated) · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
Ulcer healing · patients with Buerger's disease
It is very uncertain whether intravenous prostacyclin analogue changes ulcer healing compared with intravenous prostaglandin analogue (very low certainty).
1 finding from 1 review
Complete relief of pain · patients with Buerger's disease
Intravenous prostacyclin analogue showed no clear difference in complete relief of pain compared with intravenous prostaglandin analogue (low certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in ulcer healing compared with placebo (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in complete relief of rest pain compared with placebo (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with placebo (moderate certainty).
1 finding from 1 review
Disability due to FAP progression Not measured · people with early‐stage TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (mental) · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of participants who died during the trial compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review